Elutia Inc. (ELUT)
ELUT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/0001104659-26-027664-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ELUT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001708527 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $12.3M |
| Net income | $53.4M |
| Operating income | -$26.9M |
| Net margin | 434.2% |
| Operating margin | -218.9% |
| Revenue growth | -15.0% |
| Cash | $36.4M |
| Total assets | $62.4M |
| P/E (computed) | 0.7× |
| P/S (computed) | 3.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "In accordance with Accounting Standards Update ( ASU ) 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated finan" | 10-Q 2026-11-10 |
| Cash and burn | $29.1M cash; operating cash flow -$12.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 44,397,650 (2026-11-06). | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-07 |
| Auditor | PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $237K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.1M | -$1.3M | -$8.1M | $29.1M | $8.1M | $17.0M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $2.4M | -$7.6M | -$8.5M | $19.9M | No debt tags | $16.8M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $3.1M | -$7.5M | -$7.8M | $28.5M | No debt tags | $17.1M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $10.3M | $70.8M | -$24.8M | $36.4M | No debt tags | $16.9M | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | $944K | -$3.9M | -$2.9M | $4.7M | $31.1M | $9.5M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $2.7M | -$9.6M | -$8.2M | $8.5M | $28.9M | $12.2M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $3.0M | -$3.9M | -$8.9M | $17.4M | $26.8M | $15.7M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $2.8M | -$9.1M | -$12.3M | $13.2M | $25.1M | $19.5M | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-05-08 |
| Latest annual report | 10-K | 2026-03-13 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 378 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.0% |
| 1 month | +6.1% |
| 3 months | -4.7% |
| Year to date | +18.3% |
| 1 year | +10.4% |
| From 52-week high | -32.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EXOZ | eXoZymes Inc. | $3.99 | +4.18% | $37.1M |
| CRBU | Caribou Biosciences Inc. | $0.3528 | -2.51% | $38.1M |
| KLRS | Kalaris Therapeutics Inc. | $1.46 | -7.30% | $34.8M |
| TIL | Instil Bio Inc. | $5.75 | -5.43% | $39.0M |
| IMA | ImageneBio Inc. | $3.20 | -7.78% | $39.9M |
| LONA | LeonaBio Inc. | $3.23 | -6.92% | $30.4M |
| INMB | INmune Bio Inc. | $0.9464 | -9.87% | $29.3M |
| CVM | Cel-Sci Corporation | $1.66 | +29.69% | $29.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier